Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins, Doug Altman, Peter C Gøtzsche et al. · BMJ · 2011 · 34.2K citations · Full text

Public Health, Biostatistics, Evidence-based Practice +16

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text

Medicine, Endocrinology, Pharmacotherapy +13

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi et al. · New England Journal of Medicine · 2019 · 6.9K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14